Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534694 | 1.00 | MAPT (0.43) | MAPTNPSR1RXFP1ADORA2BHTR1B | |
| SCHEMBL12553022 | 0.90 | MAPT (0.53) | MAPTNPSR1RXFP1ADORA2BHTR1B | |
| SCHEMBL1930482 | 0.90 | MAPT (0.53) | MAPTNPSR1RXFP1ADORA2BHTR1B | |
| SCHEMBL12020317 | 0.85 | MAPK14 (0.34) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL12020287 | 0.85 | MAPK14 (0.34) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL12020307 | 0.85 | MAPK14 (0.34) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL12534896 | 0.84 | ADORA1 (0.41) | NPSR1RXFP1ADORA2BADORA1ADORA2A | |
| SCHEMBL12534902 | 0.84 | ADORA1 (0.41) | NPSR1RXFP1ADORA2BADORA1ADORA2A | |
| SCHEMBL12534957 | 0.82 | ADORA1 (0.37) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL12534947 | 0.82 | ADORA1 (0.37) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | AADAC, CYP4X1, AGXT | MAPT 4065/4885NPSR1 2095/4885RXFP1 2797/4885 |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | CYP4X1, AHR, AGXT | MAPT 3893/4885NPSR1 1745/4885RXFP1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.